IL151154A0 - Indol-3-yl derivatives - Google Patents

Indol-3-yl derivatives

Info

Publication number
IL151154A0
IL151154A0 IL15115401A IL15115401A IL151154A0 IL 151154 A0 IL151154 A0 IL 151154A0 IL 15115401 A IL15115401 A IL 15115401A IL 15115401 A IL15115401 A IL 15115401A IL 151154 A0 IL151154 A0 IL 151154A0
Authority
IL
Israel
Prior art keywords
indol
derivatives
Prior art date
Application number
IL15115401A
Other languages
English (en)
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of IL151154A0 publication Critical patent/IL151154A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
IL15115401A 2000-02-11 2001-01-05 Indol-3-yl derivatives IL151154A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10006139A DE10006139A1 (de) 2000-02-11 2000-02-11 Indol-3-yl-Derivate
PCT/EP2001/000084 WO2001058893A2 (fr) 2000-02-11 2001-01-05 Derives d'indol-3-yl

Publications (1)

Publication Number Publication Date
IL151154A0 true IL151154A0 (en) 2003-04-10

Family

ID=7630611

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15115401A IL151154A0 (en) 2000-02-11 2001-01-05 Indol-3-yl derivatives

Country Status (28)

Country Link
US (1) US6743810B2 (fr)
EP (1) EP1254133B9 (fr)
JP (1) JP4938194B2 (fr)
KR (1) KR20020073585A (fr)
CN (1) CN1214026C (fr)
AR (1) AR027398A1 (fr)
AT (1) ATE293620T1 (fr)
AU (2) AU2001231664C1 (fr)
BR (1) BR0108154A (fr)
CA (1) CA2399813C (fr)
CO (1) CO5261548A1 (fr)
CZ (1) CZ20022616A3 (fr)
DE (2) DE10006139A1 (fr)
EC (1) ECSP013923A (fr)
ES (1) ES2240400T3 (fr)
HK (1) HK1051863A1 (fr)
HU (1) HUP0302671A2 (fr)
IL (1) IL151154A0 (fr)
MX (1) MXPA02007732A (fr)
NO (1) NO20023770D0 (fr)
NZ (1) NZ521260A (fr)
PE (1) PE20011125A1 (fr)
PL (1) PL356427A1 (fr)
PT (1) PT1254133E (fr)
RU (1) RU2257380C2 (fr)
SK (1) SK11152002A3 (fr)
WO (1) WO2001058893A2 (fr)
ZA (1) ZA200207273B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040063790A1 (en) * 1996-05-31 2004-04-01 The Scripps Research Institute Methods for inhibition of angiogenesis
US20040138284A1 (en) * 2000-02-11 2004-07-15 Matthias Wiesner Indol-3-yl derivatives
WO2002018377A1 (fr) * 2000-08-29 2002-03-07 Pharmacia Corporation Composes contenant un systeme de noyau bicyclique et utiles en tant qu'antagonistes de l'integrine alpha v beta 3
SI1381382T1 (sl) * 2000-11-01 2009-04-30 Merck Patent Gmbh Postopki in sestavki za zdravljenje oäśesnih bolezni
GB0028367D0 (en) * 2000-11-21 2001-01-03 Celltech Chiroscience Ltd Chemical compounds
JP4615826B2 (ja) * 2001-01-29 2011-01-19 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 置換インドールおよびインテグリンアンタゴニストとしてのそれらの使用
US6872730B2 (en) 2001-04-27 2005-03-29 3-Dimensional Pharmaceuticals, Inc. Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists
EP1411926B1 (fr) * 2001-08-01 2005-06-01 MERCK PATENT GmbH Inhibiteurs de l'integrine pour le traitement de maladies des yeux
PL371281A1 (en) * 2002-02-14 2005-06-13 Merck Patent Gmbh Methods and compositions for the treatment of eye diseases
US20070208026A1 (en) * 2003-04-07 2007-09-06 Liu Kevin N-Containing Heteroaromatic Compounds As Modulators Of Ppars And Methods Of Treating Metabolic Disorders
CA2523245C (fr) * 2003-04-28 2012-03-06 Bayer Pharmaceuticals Corporation Derives d'acide indole acetique et leur utilisation en tant qu'agents pharmaceutiques
US7211588B2 (en) 2003-07-25 2007-05-01 Zentaris Gmbh N-substituted indolyl-3-glyoxylamides, their use as medicaments and process for their preparation
DE10337863A1 (de) * 2003-08-18 2005-03-17 Merck Patent Gmbh Verwendung von Chromen-4-on-Derivaten
CA2540730C (fr) * 2003-10-01 2012-08-21 Merck Patent Gmbh Antagonistes d'integrine alfavbeta3 et alfavbeta6 en tant qu'agents antifibrosants
JP2007536344A (ja) * 2004-05-04 2007-12-13 ノボ　ノルディスク　アクティーゼルスカブ 新規のインドール誘導体
EP1828144A2 (fr) * 2004-11-12 2007-09-05 OSI Pharmaceuticals, Inc. Antagonistes de l'integrine utiles en tant qu'agents anticancereux
US7777040B2 (en) 2005-05-03 2010-08-17 Cgi Pharmaceuticals, Inc. Certain substituted ureas, as modulators of kinase activity
CN102335168B (zh) * 2011-10-25 2014-04-02 合肥博太医药生物技术发展有限公司 吲哚-3-甲醇、二吲哚甲烷及其衍生物在制备治疗骨质疏松药物中的应用
AR094812A1 (es) * 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
CA2956270C (fr) 2014-08-18 2022-08-09 Eisai R&D Management Co., Ltd. Sel de derive de pyridine monocyclique et son cristal
JPWO2019189241A1 (ja) 2018-03-28 2021-03-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 肝細胞癌治療剤

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT290523B (de) * 1962-01-05 1971-06-11 Merck & Co Inc Verfahren zur Herstellung neuer α-(3-Indolyl)-carbonsäuren
GB1148909A (en) * 1965-04-19 1969-04-16 Sumitomo Chemical Co Process for production of novel phenylhydrazone and phenylhydrazine derivatives
US4824850A (en) * 1982-05-18 1989-04-25 University Of Florida Brain-specific drug delivery
US4983615A (en) * 1989-06-28 1991-01-08 Hoechst-Roussel Pharmaceuticals Inc. Heteroarylamino- and heteroaryloxypyridinamine compounds which are useful in treating skin disorders
IT1244548B (it) * 1991-02-06 1994-07-15 Poli Ind Chimica Spa Derivati della 5-oxo-l-prolina e loro applicazioni farmaceutiche
GB9225141D0 (en) 1992-12-01 1993-01-20 Smithkline Beecham Corp Chemical compounds
JP2000508319A (ja) 1996-04-10 2000-07-04 メルク エンド カンパニー インコーポレーテッド αｖβ３拮抗薬
PT923548E (pt) * 1996-08-27 2003-06-30 Wyeth Corp 4-aminoetoxi-indolos como agonistas d2 da dopaminae como ligandos da 5ht1a
AU1687699A (en) * 1997-12-25 1999-07-19 Yamanouchi Pharmaceutical Co., Ltd. Nitrogenous heterocyclic derivatives
MXPA00008216A (es) * 1998-02-23 2004-11-22 Univ South Alabama Acidos indol-3-propionicos, sales y esteres de los mismos utilizados como medicamentos.
AU765427B2 (en) * 1998-02-25 2003-09-18 Genetics Institute, Llc Inhibitors of phospholipase enzymes
AU3386299A (en) * 1998-04-08 1999-10-25 American Home Products Corporation N-aryloxyethylamine derivatives for the treatment of depression
AU3386199A (en) * 1998-04-08 1999-10-25 American Home Products Corporation N-aryloxyethyl-indoly-alkylamines for the treatment of depression (5-ht1a receptor active agents)
JP4425699B2 (ja) * 2004-05-17 2010-03-03 川崎重工業株式会社 小型滑走艇

Also Published As

Publication number Publication date
CZ20022616A3 (cs) 2002-10-16
KR20020073585A (ko) 2002-09-27
AU2001231664C1 (en) 2006-10-05
BR0108154A (pt) 2003-01-21
RU2002123332A (ru) 2004-01-10
US6743810B2 (en) 2004-06-01
ECSP013923A (es) 2002-09-27
CN1398264A (zh) 2003-02-19
AU2001231664B2 (en) 2006-02-23
EP1254133B9 (fr) 2005-09-07
DE50105955D1 (de) 2005-05-25
PE20011125A1 (es) 2001-11-07
CA2399813A1 (fr) 2001-08-16
JP2003530319A (ja) 2003-10-14
WO2001058893A3 (fr) 2002-04-18
US20030045728A1 (en) 2003-03-06
WO2001058893A2 (fr) 2001-08-16
AU3166401A (en) 2001-08-20
PL356427A1 (en) 2004-06-28
CN1214026C (zh) 2005-08-10
ZA200207273B (en) 2003-12-10
HUP0302671A2 (hu) 2003-12-29
EP1254133B1 (fr) 2005-04-20
NO20023770L (no) 2002-08-09
JP4938194B2 (ja) 2012-05-23
ES2240400T3 (es) 2005-10-16
SK11152002A3 (sk) 2003-01-09
EP1254133A2 (fr) 2002-11-06
DE10006139A1 (de) 2001-08-16
CA2399813C (fr) 2010-03-09
NZ521260A (en) 2004-02-27
RU2257380C2 (ru) 2005-07-27
ATE293620T1 (de) 2005-05-15
CO5261548A1 (es) 2003-03-31
MXPA02007732A (es) 2002-10-11
PT1254133E (pt) 2005-09-30
AR027398A1 (es) 2003-03-26
NO20023770D0 (no) 2002-08-09
HK1051863A1 (en) 2003-08-22

Similar Documents

Publication Publication Date Title
EG22695A (en) Novel phenyl-propargylether derivatives
IL152783A0 (en) 2-aminocarbonyl-9h-purine derivatives
HRP20030055A2 (en) 4-phenyl-pyridine derivatives
IL150841A0 (en) 1h-imidazopyridine derivatives
AU3166401A (en) Indol-3-yl derivatives
AU2001231664A1 (en) Indol-3-yl derivatives
AU8664701A (en) Oxindole derivatives
IL155103A0 (en) Substituted c-cyclohexylmethylamine derivatives
AU8993701A (en) Substituted 1-aminobutan-3-ol derivatives
IL150557A0 (en) Substituted aminomethyl-phenyl-cyclohexane derivatives
PL356565A1 (en) Aminosulfonylbiphenyl derivatives
IL150558A0 (en) Aminomethyl-phenyl-cyclohexanone derivatives
AU2163202A (en) 5-amino-1-pentene-3-ol substituted derivatives
EP1408955A4 (fr) Nouveaux derives de metallotexaphyrine
IL151598A0 (en) 2-phenylpyran-4-one derivatives
GB0031724D0 (en) Indole derivatives
GB0119696D0 (en) Indole derivatives
GB0119820D0 (en) Indole derivatives
SI1322590T1 (sl) Substituirani 5-amino-1-penten-3-olni derivati
SI1246793T1 (en) Substituted aminomethyl-phenyl-cyclohexane derivatives
GB0021639D0 (en) Maurotoxin derivatives
HK1054937A1 (en) 1-Methylcarbapenem derivatives